Welcome to our dedicated page for Iovance Biotherp SEC filings (Ticker: IOVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpreting a 200-page biotech filing packed with T-cell data is no small task. Iovance Biotherapeutics’ SEC documents weave together clinical trial efficacy, manufacturing scale-up plans and cash-burn projections—details investors need yet rarely have time to unravel.
Stock Titan’s platform turns that challenge into a two-minute read. Our AI delivers line-by-line explanations of each Iovance quarterly earnings report 10-Q filing, highlights pivotal trial endpoints in the Iovance annual report 10-K simplified, and streams Iovance Form 4 insider transactions real-time so you see executive stock moves as they post. Looking for a quick brief on a surprise data update? The Iovance 8-K material events explained module flags the section that moved the market.
Here’s what you’ll uncover on this page:
- Instant summaries that make Iovance SEC filings explained simply.
- Auto-generated dashboards comparing TIL manufacturing costs across consecutive 10-Qs.
- Alerts on Iovance insider trading Form 4 transactions before they hit the news.
- Contextual notes linking pipeline milestones to share-based compensation in the Iovance proxy statement executive compensation.
Whether you’re modeling cash runway, gauging FDA timing, or watching Iovance executive stock transactions Form 4, our AI surfaces what matters and lets you drill into original PDFs whenever you choose. Stop scrolling through dense immunotherapy jargon—start understanding Iovance SEC documents with AI and make faster, better-informed decisions.
Iovance Biotherapeutics, Inc. filed a prospectus supplement to sell up to $350.0 million of common stock through an amended at-the-market sales agreement with Jefferies LLC. The agreement replaces the prior June 16, 2023 arrangement and allows sales from time to time, with Jefferies acting as agent and receiving up to 3% of gross proceeds. The company noted its common stock traded at $2.60 per share on August 19, 2025, and estimated up to 476.5 million shares outstanding assuming sale of 134.6 million shares at $2.60. Proceeds are intended to fund the commercial launch of Amtagvi, ongoing and planned clinical trials including IOV-LUN-202 and TILVANCE-301, pipeline development, and general corporate purposes. The prospectus highlights dilution risks, potential market price volatility from resale, indemnification to Jefferies, and forward-looking risks related to clinical, regulatory, manufacturing and financing uncertainties.
Corleen M. Roche, Chief Financial Officer of Iovance Biotherapeutics (IOVA), reported equity awards dated 08/06/2025. The Form 4 discloses a grant of 300,000 stock options with a $2.58 exercise price and an expiration date listed as 08/06/2035, and 150,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock. Both awards are held directly following the reported transactions. The awards vest only if the reporting person remains employed: one-third vests on the one-year anniversary of the grant and the remaining two-thirds vest in eight equal quarterly installments over the following two years. The form is signed by Corleen Roche on 08/08/2025.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) filed a Form 8-K announcing the recruitment of Corleen Roche as Chief Financial Officer, effective August 6, 2025.
The Executive Employment Agreement, signed July 7, 2025, replaces current Principal Financial Officer Matthew W. Rosinack. Roche will receive an annual base salary of $600,000, a $50,000 one-time sign-on bonus, and is eligible for an annual discretionary bonus up to 45 % of salary.
Equity incentives under the 2018 Equity Incentive Plan comprise (i) an option to purchase 300,000 shares at the closing price on the effective date, vesting one-third after 12 months and quarterly thereafter, and (ii) 150,000 restricted stock units with identical vesting cadence. Unvested awards forfeit upon termination except where severance conditions are met.
Severance terms for a termination without cause include: (1) salary continuation for 12 months, (2) pro-rated bonus, (3) immediate vesting of unvested equity, and (4) continuation of applicable benefits. Enhanced protection applies upon a change-of-control event.
Professional background: Roche, 59, has served as CFO of CG Oncology (2024-present), Immunome (2021-2023), and Biogen U.S. (2019-2021), following senior finance roles at Sandoz and Wyeth. She began her career at PwC and holds a B.A. in Accountancy from Villanova University.
The Company issued a press release (Exhibit 99.1) on July 15, 2025 to publicly announce the appointment.
FAQ
What is the current stock price of Iovance Biotherp (IOVA)?
What is the market cap of Iovance Biotherp (IOVA)?
